AOD-9604: 10MG

£44.99

Purity: ≥ 99%

£44.99

AOD-9604: 10MG

Name: AOD-9604: 10MG
Brand: Pure Grade Labs
Price: 44.99 GBP
Availability: OutOfStock

£44.99

Purity: ≥ 99%

£44.99

ADIPOSE LIPOLYSIS: Fat cell breakdown & lipogenesis research

CARTILAGE REGENERATION: Joint repair & cartilage recovery research

GH PHARMACOLOGY: Targeted fat loss & metabolic selectivity research

GAP RESEARCH: Human efficacy & obesity pharmacotherapy research

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino acid peptide fragment derived from the C-terminal domain of human growth hormone (hGH), specifically residues 177-191 with a tyrosine substituted for phenylalanine at the N-terminal end. It was originally developed by Professor Frank Ng at Monash University, Australia in the 1990s with the objective of isolating the lipolytic domain of hGH - the region responsible for fat metabolism - while eliminating the anabolic and diabetogenic effects associated with full-length growth hormone administration.

The defining research claim for AOD-9604 is its selectivity: it is proposed to stimulate lipolysis and inhibit lipogenesis via beta-3 adrenergic receptor upregulation in adipose tissue without activating hGH receptors, without elevating IGF-1 levels, and without affecting glucose homeostasis or insulin sensitivity. In preclinical animal models, this profile was confirmed. However, this selective efficacy did not translate fully into large-scale human clinical trials, and development was terminated in 2007 following a 24-week trial of 536 subjects that failed to demonstrate sufficient weight loss for regulatory approval.

A separate and important regulatory distinction: the FDA has granted AOD-9604 "Generally Recognized As Safe" (GRAS) status when used as a food additive - a designation that evaluates safety, not efficacy, and does not imply approval for therapeutic use. AOD-9604 remains an investigational compound with no approved therapeutic indication.

Mechanism: Upregulates beta-3 adrenergic receptor expression in adipose tissue, stimulating lipolysis. Inhibits lipogenesis (conversion of non-fat food to stored fat). Does not bind hGH receptors, does not elevate IGF-1, and does not affect glucose or insulin homeostasis in preclinical models.

Development History: Multiple Phase I and Phase II human trials conducted across approximately 900 participants with a well-characterised safety profile. Phase III equivalent (24-week, n=536) failed to demonstrate adequate weight loss efficacy. Development terminated 2007. Emerging research interest in cartilage regeneration and osteoarthritis.

Amino Acid Sequence (16-aa, disulfide-bridged): H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH | Disulfide bridge: Cys(7)-Cys(14)

Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂

Molecular Weight: 1,815.1 g/mol

CAS Number: 221231-10-3

Form: Lyophilised Solid

AOD-9604 has an unusually well-documented clinical history for a compound that did not achieve approval, providing valuable pharmacokinetic and safety data. The following studies represent the key published evidence. Pure Grade Labs presents this data accurately - including the failed large-scale efficacy trial - to support informed research decisions.

American Journal of Physiology - Endocrinology & Metabolism: Effects of hGH and its lipolytic fragment AOD-9604 on lipid metabolism in obese mice and beta(3)-AR knockout mice

Hormone Research in Paediatrics (Wilding et al.): AOD-9604 in a 12-week randomised clinical trial: 1.8 kg greater weight loss vs placebo

European Cells and Materials: Intra-articular AOD-9604 with or without hyaluronic acid enhances cartilage regeneration in rabbit osteoarthritis model

References

https://pubmed.ncbi.nlm.nih.gov/11146367/

https://pubmed.ncbi.nlm.nih.gov/15134286/

https://pubmed.ncbi.nlm.nih.gov/25208511/

https://pubmed.ncbi.nlm.nih.gov/16931496/

https://pubmed.ncbi.nlm.nih.gov/16625817/

https://pubmed.ncbi.nlm.nih.gov/26275694/

https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/

https://pmc.ncbi.nlm.nih.gov/articles/PMC3136748/

Every batch of AOD-9604 supplied by Pure Grade Labs is accompanied by a Certificate of Analysis (COA) from an independent third-party analytical laboratory. AOD-9604 contains a disulfide bridge between Cys(7) and Cys(14) - the COA includes mass spectrometry confirmation of the correctly oxidised (disulfide-intact) form, as the reduced (free thiol) form is a distinct species with potentially different biological activity.

AOD-9604 is supplied as a lyophilised solid. The disulfide bridge between Cys(7) and Cys(14) is critical to the peptide's structural integrity and proposed biological activity. Reducing conditions or highly oxidising environments during reconstitution can compromise this structural feature. Handling should be performed with standard non-reducing buffers and the reconstituted solution should not be exposed to strong oxidising agents.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow the sealed vial to reach room temperature before opening to minimise moisture introduction.
Use bacteriostatic water (BAC water) as the reconstitution solvent. Add solvent slowly down the inside wall of the vial. Use a non-reducing buffer - do not use DTT or beta-mercaptoethanol-containing buffers as these will reduce the critical disulfide bridge.
Gently swirl until fully dissolved. Do not vortex. AOD-9604 is soluble in aqueous solutions and dissolves readily at room temperature.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution - the disulfide bond may be compromised by repeated freeze-thaw cycling in solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter. AOD-9604 solution should be clear and colourless.

AOD-9604 supplied by Pure Grade Labs is intended exclusively for in vitro research and laboratory use. AOD-9604 holds FDA GRAS (Generally Recognized As Safe) status as a food additive - a safety designation only, not approval for therapeutic use. It has not been approved for any therapeutic indication by the FDA, MHRA, TGA, EMA, or any other regulatory authority.

This product is not a drug, medicine, or supplement and must not be used as such.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy. The pivotal 24-week clinical trial (n=536) did not demonstrate sufficient weight loss efficacy for regulatory approval, and development was terminated in 2007.
This product must not be administered to humans or animals outside of a licensed research context.
AOD-9604 is banned by the World Anti-Doping Agency (WADA) and is tested for in athletic competition. Athletes subject to drug testing must not use this compound.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction before ordering.

All product information, research summaries, and study citations presented on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.